Insilico and SK Partner on Neuroimmune Drug Discovery Worth Up to $2.5 Billion
Insilico has entered into a significant collaboration with SK focused on AI-driven drug discovery for neuroimmune conditions. The partnership, valued at up to $2.5 billion, will leverage Insilico's AI platforms to identify and develop novel therapeutic candidates.
The collaboration combines Insilico's generative AI and deep